United States Patent 4,195,085: Timolol Maleate Glaucoma Claims, Patent Scope, and Landscape

U.S. Patent No. 4,195,085 covers topical ophthalmic use of timolol maleate for glaucoma and intraocular-pressure reduction, including polymeric inserts and liquid solutions containing 0.01% to 5% timolol maleate. The patent issued April 1, 1980, and its 17-year pre-URAA patent term expired April 1, 1997. The patent is no longer enforceable and does not create a current barrier to generic timolol ophthalmic products. [1]

What drug does U.S. Patent 4,195,085 protect?

The patent protects timolol, specifically the compound commonly administered as timolol maleate:

Active pharmaceutical ingredient: timolol
Salt form claimed: timolol hydrogen maleate, commonly called timolol maleate
Pharmacologic class: nonselective beta-adrenergic receptor antagonist
Primary ophthalmic use: reduction of elevated intraocular pressure in ocular hypertension and open-angle glaucoma
Dosage forms identified in the claims: ophthalmic solution and water-soluble polymeric insert
Claimed concentration range: 0.01% to 5%
Narrower claimed concentration range: 0.5% to 2%

Timolol reduces aqueous humor production through topical beta-blockade. The patent claims are directed to ophthalmic administration rather than oral or systemic treatment.

The chemical name in the claims contains minor spelling variations, including "thiadiazole" and "thiadiazol." Those variations do not change the identity of the claimed active compound when read with the specification and accepted pharmaceutical nomenclature.

What are the claims of U.S. Patent 4,195,085?

The patent has seven claims divided between treatment methods and compositions.

Claim	Claim type	Principal limitation	Commercial relevance
1	Method of treatment	Topically applying an intraocular-pressure-lowering amount of timolol maleate to a glaucomatous eye	Broadest treatment claim
2	Method of treatment	Administration through a water-soluble polymeric insert	Extended-release or insert delivery
3	Method of treatment	Polymeric insert is hydroxypropylcellulose	Narrow insert limitation
4	Method of treatment	Timolol administered as a 0.01% to 5% solution in an ophthalmically acceptable carrier	Solution-use claim
5	Composition	Timolol maleate in solution with a liquid ophthalmic carrier	Broad composition claim
6	Composition	Timolol maleate concentration of 0.01% to 5%	Concentration-limited composition
7	Composition	Timolol maleate concentration of 0.5% to 2%	Narrower concentration-limited composition

Claim 1 is the central claim. It requires the following elements:

A method for treating glaucoma or lowering intraocular pressure.
A glaucomatous eye.
Topical application to that eye.
An intraocular-pressure-lowering effective amount.
Timolol maleate as the active agent.

Claim 5 is the principal product claim. It requires:

An ophthalmic composition.
Topical glaucoma treatment capability.
Timolol maleate in solution.
A liquid ophthalmic carrier.
An effective amount of the active ingredient.

How broad is claim 1?

Claim 1 is broad in therapeutic and formulation terms but narrow in active ingredient. It does not require a particular bottle, preservative, pH, tonicity agent, viscosity modifier, dosing frequency, or concentration. A product that satisfied the active-ingredient and topical-use limitations could have fallen within the claim regardless of those unclaimed formulation details.

The claim does not cover every beta blocker or every glaucoma drug. It is limited to the specified timolol compound. It also does not expressly cover:

Oral timolol treatment.
Systemic beta-blocker treatment for non-ocular conditions.
Other beta blockers such as betaxolol, carteolol, levobunolol, or metipranolol.
A formulation containing a different active ingredient.
A formulation that does not use timolol maleate, subject to any applicable equivalence analysis.

Because the patent expired in 1997, this claim construction has historical and landscape value rather than current enforcement significance.

What formulations are protected by claims 2 through 7?

Polymeric inserts under claims 2 and 3

Claims 2 and 3 address a water-soluble polymeric insert. Claim 3 narrows the polymer to hydroxypropylcellulose. This was directed to sustained or controlled ocular delivery rather than the conventional multidose eye-drop format.

A hydroxypropylcellulose insert containing timolol would have presented a stronger literal claim issue than a solution using an unrelated polymer. The claim language does not broadly cover every sustained-release ophthalmic device because the polymer must be water soluble, and claim 3 specifically requires hydroxypropylcellulose.

Liquid solutions under claims 4 through 7

Claims 4 through 7 cover conventional ophthalmic solutions.

Claim 4 covers a solution containing 0.01% to 5% timolol in an ophthalmically acceptable carrier. Claims 6 and 7 apply corresponding ranges to the composition itself. The 0.5% to 2% range in claim 7 is a subset of the 0.01% to 5% range.

Typical commercial timolol maleate ophthalmic solutions have historically been marketed at 0.25% and 0.5%. A 0.5% solution falls within claim 7, while a 0.25% solution falls within claims 4 and 6 but outside claim 7. [2]

The patent does not require specific excipients. Preservatives such as benzalkonium chloride, buffering agents, sodium chloride, or purified water would generally be carrier or formulation details unless separately claimed.

When did U.S. Patent 4,195,085 lose exclusivity?

U.S. Patent 4,195,085 expired April 1, 1997, based on the 17-year term applicable to patents issued before the Uruguay Round Agreements Act changed the patent-term framework. [1]

Event	Date or status
Patent issued	April 1, 1980
Patent term basis	17 years from issue
Statutory expiration	April 1, 1997
Current enforceability	Expired
Current Orange Book protection from this patent	None
Current Paragraph IV relevance	None for this expired patent

The patent cannot currently block an abbreviated new drug application, generic launch, formulation development program, or licensing transaction. Any current exclusivity for a timolol product would have to arise from a different patent, regulatory exclusivity provision, or product-specific regulatory issue.

What is the FDA regulatory status of timolol ophthalmic products?

Timolol ophthalmic products are approved small-molecule prescription drugs. The reference product Timoptic was marketed by Merck, and FDA-approved products have included timolol maleate ophthalmic solutions in 0.25% and 0.5% strengths. [2]

The regulatory pathway for a conventional generic solution is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA requirements for the product.

Because timolol is a small molecule, biosimilar law does not apply. A timolol generic is not a biosimilar and does not proceed under the Public Health Service Act's section 351(k) pathway.

What is the Orange Book status of U.S. Patent 4,195,085?

The patent was historically associated with the protection of ophthalmic timolol products, but its term has ended. The FDA Orange Book records patents and regulatory exclusivity relevant to approved products; it does not preserve patent rights after expiration. [3]

The practical status is:

The patent is not a live Orange Book barrier.
A current ANDA applicant does not need to make a Paragraph IV certification against this expired patent.
The patent cannot support a 30-month stay under the Hatch-Waxman framework.
The patent cannot support a current patent-infringement action.
Historical Orange Book listing does not extend the patent term.

Which companies challenged or competed with the timolol reference product?

Competition developed through generic manufacturers rather than through a current challenge to Patent 4,195,085. Timolol ophthalmic solutions have been supplied by multiple generic manufacturers, including companies that have operated in the ophthalmic-generic market under different corporate ownership structures over time.

The relevant competitive groups include:

Generic manufacturers of timolol maleate 0.25% and 0.5% ophthalmic solutions.
Manufacturers of preservative-free unit-dose products.
Suppliers of gel-forming or longer-acting ophthalmic formulations.
Combination-product manufacturers, including products pairing timolol with dorzolamide or brimonidine.
Branded and generic suppliers of alternative beta-blockers and prostaglandin analogues.

The commercial competition is no longer controlled by the 1980 patent. It is driven by manufacturing cost, FDA approval status, supply reliability, preservative-free delivery, contracting, and ophthalmology prescribing patterns.

What Paragraph IV challenges affected timolol?

A Paragraph IV certification is relevant only when an ANDA applicant disputes a listed patent that has not expired or asserts that the patent is invalid or not infringed. Patent 4,195,085 expired in 1997, so it cannot support a current Paragraph IV dispute.

Historical generic entry may have involved certifications against other patents or regulatory exclusivities associated with particular timolol products. Those issues should be separated from Patent 4,195,085. The patent itself no longer creates litigation risk.

What patent litigation affects timolol ophthalmic products?

Patent 4,195,085 does not present current litigation exposure because it is expired. Later disputes involving timolol products may concern:

Gel-forming solutions.
Preservative-free containers.
Combination products.
Extended-release delivery.
Specific manufacturing processes.
Device components or packaging.
Patents covering another active ingredient in a combination product.

A competitor cannot revive the expired patent through a later formulation patent. A later patent must claim a distinct, patentable formulation, delivery system, manufacturing process, or combination.

How does the timolol patent estate compare with newer glaucoma drugs?

Product class	Typical protection focus	Current risk profile
Timolol ophthalmic solution	Active ingredient, topical method, solution concentration	Low; foundational patent expired
Prostaglandin analogues	Active compound, formulations, dosing methods, devices	Depends on product and later formulation patents
Fixed combinations	Combination composition, ratios, dosing, formulation	Higher than plain timolol where later patents remain
Gel-forming timolol products	Polymer system, viscosity, delivery profile	Product-specific patent risk
Preservative-free products	Container, unit-dose system, formulation stability	Device and formulation claims may remain relevant
Biologic ophthalmic products	Composition, manufacturing, method of use	Biosimilar and interchangeability issues may apply

Timolol's foundational patent estate is weaker than the estate for a recently launched ophthalmic product because the core active-ingredient and topical-use rights have long expired. The remaining commercial value lies in product execution and differentiated delivery.

What generic launch risks exist for timolol products?

For a standard 0.25% or 0.5% timolol maleate ophthalmic solution, patent risk from U.S. Patent 4,195,085 is zero in practical terms. The principal launch risks are regulatory and commercial:

FDA approval and product-quality compliance.
Sterility assurance.
Container-closure integrity.
Preservative control.
Extractables and leachables.
Manufacturing consistency.
Drug-shortage exposure.
Contracting and reimbursement pressure.
Substitution rules for branded and generic products.

A differentiated product may face separate patent analysis if it uses a novel gel matrix, preservative-free multidose system, insert, combination, or controlled-release device.

What geographic coverage does the patent provide?

U.S. Patent 4,195,085 provided protection only in the United States. Corresponding foreign rights, if any, would have required separate national or regional patents and would have had separate expiration dates and legal status.

The expiration of the U.S. patent does not establish freedom to operate in Canada, Europe, Japan, China, or other jurisdictions. For current international commercialization, each country requires a separate review of:

National patent family members.
Patent-term adjustments or supplementary protection certificates.
Local formulation patents.
Data exclusivity.
Regulatory approval requirements.
Manufacturing and import restrictions.

How strong is the patent estate for timolol today?

The estate is commercially weak for conventional timolol maleate solution because the principal U.S. patent expired more than two decades ago. Its historical claim coverage was meaningful because it combined:

A named active ingredient.
Topical ophthalmic administration.
Glaucoma treatment.
Solution dosage forms.
Concentration ranges.
Polymeric inserts.

Today, those same claims provide no enforceable exclusionary right. The principal residual barriers are technical and regulatory rather than patent-based.

Key Takeaways

U.S. Patent 4,195,085 covers topical timolol maleate treatment for glaucoma and elevated intraocular pressure.
Claims 2 and 3 cover water-soluble polymeric inserts, including hydroxypropylcellulose inserts.
Claims 4, 6, and 7 cover timolol ophthalmic solutions at specified concentrations.
The patent issued April 1, 1980, and expired April 1, 1997.
It cannot support a current Paragraph IV certification dispute, 30-month stay, or infringement action.
Timolol is a small molecule; biosimilar law does not apply.
Current risk for conventional generic timolol solution is primarily FDA, manufacturing, supply, and commercial risk.
Later patents may still matter for gel-forming solutions, combination products, preservative-free systems, devices, and manufacturing processes.

FAQs

Does U.S. Patent 4,195,085 cover timolol 0.5% eye drops?

Yes. A 0.5% timolol maleate ophthalmic solution falls within the concentration ranges recited in claims 4 and 6 and at the lower boundary of claim 7, assuming the other claim limitations are satisfied.

Can a generic manufacturer rely on the expiration of Patent 4,195,085?

Yes. The patent expired April 1, 1997, so it does not prevent FDA approval or commercial launch of an otherwise compliant generic timolol ophthalmic solution.

Does the patent cover timolol gel-forming ophthalmic products?

Not necessarily. The patent covers a liquid solution and a specified water-soluble polymeric insert. A later gel-forming product may require separate analysis of its polymer, rheology, formulation, container, and release-profile patents.

Are timolol maleate and timolol different for patent purposes?

Timolol is the active beta-blocker, while timolol maleate is its hydrogen maleate salt used in ophthalmic products. The claims expressly identify the hydrogen maleate form, although portions of the claim language refer to the underlying timolol compound.

Is a biosimilar application required for timolol ophthalmic solution?

No. Timolol is a chemically synthesized small molecule. A conventional generic timolol ophthalmic solution is regulated through the ANDA pathway rather than the biosimilar pathway.

References

United States Patent and Trademark Office. (1980). U.S. Patent No. 4,195,085: Ophthalmic compositions and method of treatment. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Timoptic: Timolol maleate ophthalmic solution prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1771476	⤷ Start Trial
Australia	513280	⤷ Start Trial
Belgium	846574	⤷ Start Trial
Bulgaria	60332	⤷ Start Trial
Cyprus	1023	⤷ Start Trial
United Kingdom	1524405	⤷ Start Trial
Hong Kong	67579	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,195,085

Summary for Patent: 4,195,085